GAMMA Investing LLC Acquires Shares of 2,085 Hologic, Inc. (NASDAQ:HOLX)

GAMMA Investing LLC acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,085 shares of the medical equipment provider’s stock, valued at approximately $155,000.

Other large investors also recently modified their holdings of the company. Deseret Mutual Benefit Administrators grew its position in shares of Hologic by 42.2% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 155 shares during the last quarter. Arizona State Retirement System grew its position in shares of Hologic by 0.3% in the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock valued at $4,810,000 after buying an additional 172 shares during the last quarter. Allworth Financial LP grew its position in shares of Hologic by 39.3% in the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 179 shares during the last quarter. Great Lakes Retirement Inc. grew its position in shares of Hologic by 1.6% in the 4th quarter. Great Lakes Retirement Inc. now owns 11,859 shares of the medical equipment provider’s stock valued at $847,000 after buying an additional 186 shares during the last quarter. Finally, Choate Investment Advisors grew its position in shares of Hologic by 1.3% in the 3rd quarter. Choate Investment Advisors now owns 15,732 shares of the medical equipment provider’s stock valued at $1,092,000 after buying an additional 202 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 0.4 %

HOLX stock opened at $75.98 on Friday. Hologic, Inc. has a one year low of $64.02 and a one year high of $87.88. The stock has a market capitalization of $17.83 billion, a PE ratio of 36.01, a price-to-earnings-growth ratio of 2.56 and a beta of 1.00. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The company has a fifty day moving average of $76.03 and a 200-day moving average of $72.78.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. During the same quarter last year, the business earned $1.07 earnings per share. The business’s revenue for the quarter was down 5.7% compared to the same quarter last year. As a group, analysts expect that Hologic, Inc. will post 4.01 EPS for the current year.

Insider Activity at Hologic

In related news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock worth $2,473,443 over the last 90 days. Company insiders own 1.75% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on HOLX. Raymond James raised their price objective on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Wednesday, April 10th. Evercore ISI raised their price objective on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Finally, William Blair reissued an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $87.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.